KNF approves NanoGroup IPO prospectus

The Financial Supervision Authority KNF approved the IPO prospectus of biotechnology company NanoGroup. The company’s majority shareholders include investment fund GPV (38 percent stake) and Tomasz Ciach (36 percent), the remaining shares are controlled by Startventure@Poland and other investors. The company will use the funds from the floating for research projects and hopes to raise several PLN millions. It also hopes to sign the first major partnership agreement with a large pharmaceutical company in 2019. NanoGroup is a group of companies that carry out research projects in oncology treatment. They include the effective targeting of nanoparticle combinations, early tumor diagnostic and therapeutic systems, synthetic media that mimic the function of red blood cells, and long-term storage system.